Ulcerogenic and healing impairing actions of monochloramine in rat stomachs: effects of zinc L-carnosine, polaprezinc
Laboratory studyOther animalsWith zinc (as polaprezinc)
This study tested carnosine together with zinc (as polaprezinc). Its results cannot be assigned to carnosine alone. More combination studies.
- Design
- Laboratory study
- Dose used in the study
- polaprezinc 3 to 30 mg/kg by mouth before monochloramine (120 mM); more than 10 mg/kg by mouth twice daily for healing
- Duration
- 7 days (healing study)
- What was measured
- Gastric haemorrhagic lesions and thiobarbituric acid reactants after oral monochloramine (and ammonium hydroxide with ischaemia) in rats; healing of monochloramine-induced and ethanol-induced lesions with polaprezinc; in vitro monochloramine scavenging.
What the authors reported
Oral monochloramine above 60 mM caused severe haemorrhagic gastric lesions and a marked rise in thiobarbituric acid reactants. Polaprezinc 3 to 30 mg/kg dose-dependently inhibited the lesions and the rise, and also attenuated lesions from ammonium hydroxide plus ischaemia (as did taurine). Given twice daily for 7 days at more than 10 mg/kg, it accelerated healing of monochloramine-induced lesions and countered delayed healing of ethanol-induced lesions in the presence of monochloramine. Polaprezinc scavenged monochloramine in vitro, which the authors say may partly explain its actions.
Limits of this study
Rodents lack serum carnosinase, so oral results do not carry over to people. Full text not read.
Source
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.